Immunogenomics of cholangiocarcinoma

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Immunogenomics of cholangiocarcinoma. / Gehl, Virag; O'Rourke, Colm J; Andersen, Jesper B.

In: Hepatology, 2023.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Gehl, V, O'Rourke, CJ & Andersen, JB 2023, 'Immunogenomics of cholangiocarcinoma', Hepatology. https://doi.org/10.1097/HEP.0000000000000688

APA

Gehl, V., O'Rourke, C. J., & Andersen, J. B. (2023). Immunogenomics of cholangiocarcinoma. Hepatology. https://doi.org/10.1097/HEP.0000000000000688

Vancouver

Gehl V, O'Rourke CJ, Andersen JB. Immunogenomics of cholangiocarcinoma. Hepatology. 2023. https://doi.org/10.1097/HEP.0000000000000688

Author

Gehl, Virag ; O'Rourke, Colm J ; Andersen, Jesper B. / Immunogenomics of cholangiocarcinoma. In: Hepatology. 2023.

Bibtex

@article{d6fa94a3d63949068f87bd71782b6447,
title = "Immunogenomics of cholangiocarcinoma",
abstract = "The development of cholangiocarcinoma spans years, if not decades, during which the immune system becomes corrupted and permissive to primary tumor development and metastasis. This involves subversion of local immunity at tumor sites, as well as systemic immunity and the wider host response. While immune dysfunction is a hallmark of all cholangiocarcinoma, the specific steps of the cancer-immunity cycle that are perturbed differ between patients. Heterogeneous immune functionality impacts the evolutionary development, pathobiological behavior and therapeutic response of these tumors. Integrative genomic analyses of thousands of primary tumors have supported a biological rationale for immune-based stratification of patients, encompassing immune cell composition and functionality. However, discerning immune alterations responsible for promoting tumor initiation, maintenance, and progression from those present as bystander events remains challenging. Functionally uncoupling the tumor-promoting or tumor-suppressing roles of immune profiles will be critical for identifying new immunomodulatory treatment strategies and associated biomarkers for patient stratification. This review will discuss the immunogenomics of cholangiocarcinoma, including the impact of genomic alterations on immune functionality, subversion of the cancer-immunity cycle, as well as clinical implications for existing and novel treatment strategies.",
author = "Virag Gehl and O'Rourke, {Colm J} and Andersen, {Jesper B}",
note = "Copyright {\textcopyright} 2023 American Association for the Study of Liver Diseases.",
year = "2023",
doi = "10.1097/HEP.0000000000000688",
language = "English",
journal = "Hepatology",
issn = "0270-9139",
publisher = "JohnWiley & Sons, Inc.",

}

RIS

TY - JOUR

T1 - Immunogenomics of cholangiocarcinoma

AU - Gehl, Virag

AU - O'Rourke, Colm J

AU - Andersen, Jesper B

N1 - Copyright © 2023 American Association for the Study of Liver Diseases.

PY - 2023

Y1 - 2023

N2 - The development of cholangiocarcinoma spans years, if not decades, during which the immune system becomes corrupted and permissive to primary tumor development and metastasis. This involves subversion of local immunity at tumor sites, as well as systemic immunity and the wider host response. While immune dysfunction is a hallmark of all cholangiocarcinoma, the specific steps of the cancer-immunity cycle that are perturbed differ between patients. Heterogeneous immune functionality impacts the evolutionary development, pathobiological behavior and therapeutic response of these tumors. Integrative genomic analyses of thousands of primary tumors have supported a biological rationale for immune-based stratification of patients, encompassing immune cell composition and functionality. However, discerning immune alterations responsible for promoting tumor initiation, maintenance, and progression from those present as bystander events remains challenging. Functionally uncoupling the tumor-promoting or tumor-suppressing roles of immune profiles will be critical for identifying new immunomodulatory treatment strategies and associated biomarkers for patient stratification. This review will discuss the immunogenomics of cholangiocarcinoma, including the impact of genomic alterations on immune functionality, subversion of the cancer-immunity cycle, as well as clinical implications for existing and novel treatment strategies.

AB - The development of cholangiocarcinoma spans years, if not decades, during which the immune system becomes corrupted and permissive to primary tumor development and metastasis. This involves subversion of local immunity at tumor sites, as well as systemic immunity and the wider host response. While immune dysfunction is a hallmark of all cholangiocarcinoma, the specific steps of the cancer-immunity cycle that are perturbed differ between patients. Heterogeneous immune functionality impacts the evolutionary development, pathobiological behavior and therapeutic response of these tumors. Integrative genomic analyses of thousands of primary tumors have supported a biological rationale for immune-based stratification of patients, encompassing immune cell composition and functionality. However, discerning immune alterations responsible for promoting tumor initiation, maintenance, and progression from those present as bystander events remains challenging. Functionally uncoupling the tumor-promoting or tumor-suppressing roles of immune profiles will be critical for identifying new immunomodulatory treatment strategies and associated biomarkers for patient stratification. This review will discuss the immunogenomics of cholangiocarcinoma, including the impact of genomic alterations on immune functionality, subversion of the cancer-immunity cycle, as well as clinical implications for existing and novel treatment strategies.

U2 - 10.1097/HEP.0000000000000688

DO - 10.1097/HEP.0000000000000688

M3 - Journal article

C2 - 37972940

JO - Hepatology

JF - Hepatology

SN - 0270-9139

ER -

ID: 381218903